Apyx Medical Corp (APYX) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Apyx Medical Corporation is an advanced energy technology company operating in two segments: Advanced Energy (Renuvion and J-Plasma products for cosmetic and hospital surgery) and OEM (manufacturing contracts). The company is a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenue | $11.49M | $11.98M | $33.88M | $37.69M |
| Gross Profit | $6.95M | $7.98M | $20.40M | $24.83M |
| Gross Margin | 60.5% | 66.6% | 60.2% | 65.9% |
| Net Loss (Stockholders) | $(4.70M) | $(4.63M) | $(18.84M) | $(9.11M) |
| Loss Per Share | $(0.14) | $(0.13) | $(0.54) | $(0.26) |
| Cash & Equivalents | $28.01M | $22.13M | $28.01M | $22.13M |
| Long-Term Debt (Net) | $33.85M | $33.19M | $33.85M | $33.19M |
| Operating Cash Flow (9M) | $(15.11M) | $(3.04M) | $(15.11M) | $(3.04M) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 4.1% in Q3 and 10.1% YTD. The Advanced Energy segment declined 5.6% (Q3) and 15.2% (YTD) due to lower generator sales and average selling prices, partially offset by a 9% increase in handpiece unit volume. The OEM segment grew 2.8% (Q3) and 14.5% (YTD).
- Margin Compression: Gross margins declined from 66.6% to 60.5% in Q3, driven by a lower mix of high-margin generator sales and a higher proportion of OEM sales.
- Expense Reduction: Salaries and related costs dropped 22.6% in Q3, primarily due to the reversal of the entire annual bonus accrual. SG&A expenses decreased 11.4% due to lower commissions and advertising.
- Interest Expense: Interest expense increased significantly (144% in Q3) due to the Perceptive Credit Agreement, though interest income also rose due to higher cash balances.
Outlook, Management Commentary, and Risks
- Restructuring: In November 2024, the company reduced its US workforce by nearly 25% and reduced the board of directors. This is expected to generate approximately $4.3 million in annualized cost savings, with a one-time charge of ~$0.6 million in Q4 2024.
- Capital Raise: On November 7, 2024, the company closed a $7.0 million registered direct offering.
- Debt Covenant Amendment: The Perceptive Credit Agreement was amended to reduce revenue targets and introduce a maximum operating expense covenant ($40M for 2025). The company was in compliance as of September 30, 2024.
- Liquidity: The company anticipates continued losses in the near term. Cash burn was $15.1M for the first nine months of 2024. Management aims to achieve cash-flow breakeven through cost reductions.
- Market Dynamics: Management notes that GLP-1 weight loss drugs may initially suppress liposuction procedures but could eventually drive demand for body contouring (Renuvion's core market) due to loose skin issues.
- Legal Contingencies: The company faces product liability lawsuits. Estimated losses for probable claims range from $1.45M to $1.95M (2022 cases) and $1.3M to $1.5M (2024 cases). Management believes insurance covers these, but disputes with carriers exist.
Investor Verification Checklist
- Verify the impact of the November 2024 workforce reduction on Q4 2024 operating expenses and the realization of the projected $4.3M annual savings.
- Monitor compliance with the amended Perceptive Credit Agreement covenants, specifically the $38.3M revenue target for the quarter ended September 30, 2024, and the $40M operating expense cap for 2025.
- Assess the trajectory of Advanced Energy generator sales versus handpiece consumables to determine if margin compression stabilizes.
- Review the status of product liability litigation and potential insurance coverage disputes, which could materially impact cash flow if coverage is denied.
- Track the utilization of the $7.0M raised in the November 2024 offering and the remaining cash runway given the current burn rate.